Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.53 |
| ▸ | SKP1 | P63208 | 2/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30150192 | 0.95 | MAPT (0.56) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL594965 | 0.95 | MAPT (0.56) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL6356496 | 0.87 | GPR119 (0.59) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL6352769 | 0.86 | CKS1B (0.59) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL30316131 | 0.86 | CKS1B (0.53) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL6350309 | 0.86 | MEN1 (0.53) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL1990159 | 0.86 | CKS1B (0.53) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL5236861 | 0.84 | MAPT (0.61) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL25322081 | 0.83 | CKS1B (0.55) | CKS1BSKP1SKP2GPR119MAPT | |
| SCHEMBL27203577 | 0.83 | MAPT (0.56) | CKS1BSKP1SKP2GPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022067114-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-6897219-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2005-05-24 | — | — | US | disclosed |
| US-6825189-B1 | TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION | NEUROSEARCH A/S (DK) | 2004-11-30 | — | — | US | disclosed |
| EP-1027336-B1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH AS (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | NEUROSEARCH A/S | 2004-04-15 | — | — | US | disclosed |
| EP-1027336-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021834-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | CKS1B 2531/4885SKP1 3548/4885SKP2 2674/4885 |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | OGFR, CBR3, OGFRL1 | CKS1B 2253/4885SKP1 1425/4885SKP2 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.